Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

medac gesellschaft für klinische spezialpräparate gmbh - methotrexatum inn - stungulyf, lausn í áfylltum lyfjapenna - 10 mg

Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

medac gesellschaft für klinische spezialpräparate gmbh - methotrexatum inn - stungulyf, lausn í áfylltum lyfjapenna - 12,5 mg

Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

medac gesellschaft für klinische spezialpräparate gmbh - methotrexatum inn - stungulyf, lausn í áfylltum lyfjapenna - 15 mg

Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

medac gesellschaft für klinische spezialpräparate gmbh - methotrexatum inn - stungulyf, lausn í áfylltum lyfjapenna - 22,5 mg

Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

teva b.v.* - lisdexamfetaminum dimesylate - hart hylki - 30 mg

Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

teva b.v.* - lisdexamfetaminum dimesylate - hart hylki - 50 mg

Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

teva b.v.* - lisdexamfetaminum dimesylate - hart hylki - 70 mg

Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

krka d.d. novo mesto* - dabigatranum etexilatum mesílat - hart hylki - 110 mg

Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

krka d.d. novo mesto* - dabigatranum etexilatum mesílat - hart hylki - 150 mg

Den Europæiske Union - islandsk - EMA (European Medicines Agency)

viatris limited - clopidogrel besilate - peripheral vascular diseases; stroke; myocardial infarction - blóðþurrðandi lyf - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). l hækkun, bráð myndun stíflufleygs, ásamt asa í læknisfræðilega sjúklingum rétt fyrir segaleysandi meðferð. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. nánari upplýsingar er að vísa til kafla 5.